Solid Biosciences Inc. 8-K

What Happened
Solid Biosciences Inc. (SLDB) filed an 8-K (Item 5.02) announcing that, effective 4:00 p.m. ET on April 10, 2026, director Ilan Ganot resigned from the Board’s Class III and was simultaneously appointed to fill a vacancy in Class I. The Board adjusted the class counts — reducing Class III directors to three and increasing Class I directors to three. Mr. Ganot’s new Class I term expires at the Company’s 2028 Annual Meeting of Stockholders.

Key Details

• Effective date/time: April 10, 2026 at 4:00 p.m. Eastern Time.
• Board composition change: Class III decreased to 3 directors; Class I increased to 3 directors.
• Term impact: Mr. Ganot will not stand for re-election at the 2027 Annual Meeting; his Class I term expires at the 2028 Annual Meeting.
• Corporate governance note: Company will seek advisory ratification of Mr. Ganot’s appointment at the 2026 Annual Meeting of Stockholders.
• Compensation: No changes to Mr. Ganot’s compensation and no payment due in connection with the move.

Why It Matters
This is a governance reshuffle, not a change in personnel or pay — the move rebalances board class membership and changes when Mr. Ganot will next face stockholder election. For investors, the filing signals the company is aligning director terms for board stability and continuity; there is no immediate financial impact disclosed.